A dynamic force in the fight against infectious diseases

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens.

Learn More

A ground-breaking advancement

Fungerps: our novel anti-fungal agents

The fungerps are an innovative new weapon for potential deployment against a range of serious fungal infections.

Learn More

Innovation in action

Life-Threatening Infections

We’re bringing new weapons to the fight against debilitating and life-threatening infections that pose serious challenges in hospitals.

Learn More

Serving Unmet Needs

Anti-microbial resistance threat

The increase of antifungal-resistant pathogens is reported globally. Considering the limited treatment options and often deadly outcomes of these diseases, antifungal resistance is a significant global health threat.

Learn More

Our pipeline

Our work on meaningful scientific breakthroughs has the power to change lives.

Learn More

Latest news

  • 05/28/25

    SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

    Read More >
  • 05/15/25

    SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Read More >
  • 04/08/25

    SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

    Read More >
  • 03/12/25

    SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

    Read More >
  • 12/18/24

    SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

    Read More >
  • 11/06/24

    SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Read More >
  • 10/10/24

    SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

    Read More >
  • 10/03/24

    SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

    Read More >
  • 08/27/24

    SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

    Read More >
  • 08/08/24

    SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    Read More >

View All

Interested in learning more about our products, partnership opportunities and more?

Learn More

Make a Difference

Join Our Team

Our people are on a mission to cure infectious diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join SCYNEXIS in the fight against fungal disease.

Learn More